SODIUM BICARBONATE injection, solution

দেশ: মার্কিন যুক্তরাষ্ট্র

ভাষা: ইংরেজি

সূত্র: NLM (National Library of Medicine)

সক্রিয় উপাদান:

SODIUM BICARBONATE (UNII: 8MDF5V39QO) (SODIUM CATION - UNII:LYR4M0NH37)

থেকে পাওয়া:

Henry Schein, Inc.

প্রশাসন রুট:

INTRAVENOUS

প্রেসক্রিপশন টাইপ:

PRESCRIPTION DRUG

থেরাপিউটিক ইঙ্গিত:

Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time int

পণ্য সারাংশ:

Sodium Bicarbonate Injection, USP is supplied in the following dosage forms. 4.2% 5 mEq/10mL (0.5 mEq/mL) 10 mL in 1 Single Dose Syringe Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Hospira, Inc., Lake Forest, IL 60045 USA  ABBOJECT® is a trademark of the Abbott group of companies. LAB-1017-3.0 01/2018

অনুমোদন অবস্থা:

Abbreviated New Drug Application

পণ্য বৈশিষ্ট্য

SODIUM BICARBONATE- SODIUM BICARBONATE INJECTION, SOLUTION
HENRY SCHEIN, INC.
----------
SODIUM BICARBONATE
FOR THE CORRECTION OF METABOLIC ACIDOSIS
AND OTHER CONDITIONS REQUIRING
SYSTEMIC ALKALINIZATION.
ABBOJECT® Syringe
Rx only
Hospira
DESCRIPTION
Sodium Bicarbonate Injection, USP is a sterile, nonpyrogenic,
hypertonic solution of
sodium bicarbonate (NaHCO ) in water for injection for administration
by the
intravenous route as an electrolyte replenisher and systemic
alkalizer.
The solution is offered in a concentration of 4.2%. See table in HOW
SUPPLIED section
for contents and characteristics.
The solution has an approximate pH of 8.0 (7.0 – 8.5). It contains
no bacteriostat,
antimicrobial agent or added buffer and is intended only for use as a
single-dose
injection. When smaller doses are required, the unused portion should
be discarded with
the entire unit.
Sodium bicarbonate, 42 mg is equal to 0.5 milliequivalent each of Na+
and HCO ¯.
Sodium Bicarbonate, USP is chemically designated NaHCO , a white
crystalline powder
soluble in water.
Water for Injection, USP is chemically designated H O.
CLINICAL PHARMACOLOGY
Intravenous sodium bicarbonate therapy increases plasma bicarbonate,
buffers excess
hydrogen ion concentration, raises blood pH and reverses the clinical
manifestations of
acidosis.
Sodium bicarbonate in water dissociates to provide sodium (Na+) and
bicarbonate
(HCO ¯) ions. Sodium (Na+) is the principal cation of the
extracellular fluid and plays a
large part in the therapy of fluid and electrolyte disturbances.
Bicarbonate (HCO ¯) is a
normal constituent of body fluids and the normal plasma level ranges
from 24 to 31
mEq/liter. Plasma concentration is regulated by the kidney through
acidification of the
urine when there is a deficit or by alkalinization of the urine when
there is an excess.
Bicarbonate anion is considered "labile" since at a proper
concentration of hydrogen ion
(H+) it may be converted to carbonic acid (H CO ) and thence to its
volatile form,
carbon dioxide (CO ) excreted by